IDC group (n = 14,547) | ILC group (n = 528) | P-value | |
---|---|---|---|
Age | |||
Mean ± SD | 48.5 ± 10.3 | 48.9 ± 9.3 | 0.297 |
Median (range) | 47.0 (19.0 to 93.0) | 47.0 (24.0 to 82.0) | 0.321 |
<50 | 8736 (60.1) | 323 (61.2) | 0.109 |
50≤ | 5811 (39.9) | 205 (38.8) | |
Tumor size | |||
Mean ± SD | 2.3 ± 1.4 | 2.9 ± 1.9 | <0.001 |
Median (range) | 2.0 (0.1 to 16.0) | 2.5 (0.3 to 14.0) | <0.001 |
T ≤ 2 cm | 7,556 (51.9) | 218 (41.3) | <0.001 |
2 cm < T ≤ 5 cm | 6,341 (43.6) | 251 (47.5) | |
5 cm < T | 650 (5.2) | 59 (11.2) | |
Nodal status | |||
0 | 8238 (56.6) | 289 (54.7) | 0.248 |
1 to 3 | 4067 (28.0) | 141 (26.7) | |
4 to 9 | 1481 (10.2) | 67 (12.7) | |
10≤ | 761 (5.2) | 31 (5.9) | |
TNMstage | |||
stage I | 5323 (36.6) | 166 (31.4) | 0.001 |
stage II | 6819 (46.9) | 244 (46.2) | |
stage III | 2405 (16.5) | 118 (22.4) | |
Lymphatic invasion | |||
no | 9,337 (64.2) | 343 (65.0) | 0.714 |
yes | 5,210 (35.8) | 185 (35.0) | |
Vascular invasion | |||
no | 11,794 (81.1) | 387 (73.3) | <0.001 |
yes | 2,753 (18.9) | 141 (26.7) | |
Estrogen receptor status | |||
negative | 5,698 (39.2) | 103 (19.5) | <0.001 |
positive | 8,849 (60.8) | 425 (80.5) | |
Progesterone receptor status | |||
negative | 6,370 (43.8) | 134 (25.4) | <0.001 |
positive | 8,177 (56.2) | 394 (74.6) | |
HER2 | |||
negative | 11,381 (78.2) | 496 (93.9) | <0.001 |
positive | 3,166 (21.8) | 32 (6.1) | |
Radiation therapy | |||
no | 6,570 (45.2) | 265 (50.2) | 0.023 |
yes | 7,977 (54.8) | 263 (49.8) | |
Chemotherapy | |||
no | 2,499 (17.2) | 96 (18.2) | 0.549 |
yes | 12,048 (82.8) | 432 (81.8) | |
Hormonal therapy | |||
no | 4,549 (31.3) | 81 (15.3) | <0.001 |
yes | 9,998 (68.7) | 447 (84.7) | |
Surgery | |||
mastectomy | 8,112 (55.8) | 354 (67.1) | <0.001 |
breast conserving surgery | 6,435 (44.2) | 174 (32.9) | |
Molecular subtype | |||
luminal A | 8,196 (56.3) | 439 (83.2) | <0.001 |
luminal B | 1,638 (11.3) | 25 (4.7) | |
HER2-overexpression | 1,528 (10.5) | 7 (1.3) | |
Triple negative | 3,185 (21.9) | 57 (10.8) |